These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21661412)

  • 1. Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride.
    Nakamura M; Ohmiya N; Miyahara R; Ando T; Watanabe O; Kawashima H; Itoh A; Hirooka Y; Niwa Y; Goto H
    Hepatogastroenterology; 2011; 58(106):453-8. PubMed ID: 21661412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serotonin 5- HT4 receptor agonist (mosapride citrate)].
    Odaka T; Suzuki T; Seza A; Yamaguchi T; Saisho H
    Nihon Rinsho; 2006 Aug; 64(8):1491-4. PubMed ID: 16898619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome.
    Kanazawa M; Watanabe S; Tana C; Komuro H; Aoki M; Fukudo S
    Neurogastroenterol Motil; 2011 Aug; 23(8):754-e332. PubMed ID: 21615623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome.
    Mansour NM; Ghaith O; El-Halabi M; Sharara AI
    Am J Gastroenterol; 2012 May; 107(5):792-3. PubMed ID: 22552247
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy.
    Wei W; Ge ZZ; Lu H; Gao YJ; Hu YB; Xiao SD
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1605-8. PubMed ID: 17683491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
    Liu Z; Sakakibara R; Odaka T; Uchiyama T; Uchiyama T; Yamamoto T; Ito T; Asahina M; Yamaguchi K; Yamaguchi T; Hattori T
    Mov Disord; 2005 Jun; 20(6):680-6. PubMed ID: 15719424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS.
    Hasler WL; Saad RJ; Rao SS; Wilding GE; Parkman HP; Koch KL; McCallum RW; Kuo B; Sarosiek I; Sitrin MD; Semler JR; Chey WD
    Am J Physiol Gastrointest Liver Physiol; 2009 Dec; 297(6):G1107-14. PubMed ID: 19808653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DSP-6952, a novel 5-HT
    Mine Y; Itakura T; Oku S; Asada R; Shimizu I
    Eur J Pharmacol; 2018 May; 826():123-132. PubMed ID: 29428470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of the diagnostic value of video capsule endoscopy in patients initially classified as irritable bowel syndrome.
    Ohlsson B; Bengtsson M; Nielsen J; Toth E
    Eur J Intern Med; 2009 Jan; 20(1):48-52. PubMed ID: 19237092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment.
    El-Salhy M; Hatlebakk JG; Gilja OH; Hausken T
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):435-43. PubMed ID: 24580043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M; McKinzie S; Fox J; Foxx-Orenstein A; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice.
    Lee MJ; Cho KH; Park HM; Sung HJ; Choi S; Im W
    Eur J Pharmacol; 2014 Jul; 735():115-22. PubMed ID: 24769304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
    Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
    Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro.
    Kim HS; Choi EJ; Park H
    Neurogastroenterol Motil; 2008 Feb; 20(2):169-76. PubMed ID: 17931343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.